SINTX Technologies (SINT) Q1 2025 earnings summary

Executive summary

• Accelerated transition to a pure-play medical device innovator focused on silicon nitride for biomedical, orthopedic, spinal fusion, dental, and antipathogenic applications, leveraging unique infection-resistant properties.

• Strategic shift includes operational streamlining, workforce reduction, ceasing armor plant operations, and divesting non-core subsidiaries to prioritize high-return growth projects.

• Disposed of subsidiary TA & T in Q1 2025, reducing liabilities and streamlining operations.

• Strategic redirection targets large, underserved clinical needs in infection resistance and tissue healing.

Financial highlights

• Q1 2025 net loss was $2.3 million, compared to $0.9 million in Q1 2024.

• Total revenue for Q1 2025 was $369,000, down 46% year-over-year; grant and contract revenue fell 79%.

• Gross profit for Q1 2025 was $123,000, down 73% from Q1 2024.

• Cash and cash equivalents increased to $6.5 million as of March 31, 2025, nearly doubling from $3.6 million at year-end 2024.

• Net cash used in operating activities for Q1 2025 was $1.3 million, down from $2.7 million in Q1 2024 due to cost optimization.

Outlook and guidance

• Management believes there is no significant uncertainty regarding going concern status through at least May 2026, following cost reductions and a $5 million capital raise.

• Strategic focus on expanding silicon nitride use in medical and antipathogenic markets, licensing, and commercialization, with ongoing efforts to raise additional equity or debt financing.

• Select asset divestitures and disciplined capital investment planned to support long-term shareholder value.